Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 314

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults

Open access
Jones, Stacie M., Sicherer, Scott H., Burks, A. Wesley, Leung, Donald Y.M., Lindblad, Robert W., Dawson, Peter, Henning, Alice K., Berin, M. Cecilia, Chiang, David, Vickery, Brian P., Pesek, Robbie D., Cho, Christine B., Davidson, Wendy F., Plaut, Marshall, Sampson, Hugh A., Wood, Robert A.·2017·Journal of Allergy and Clinical Immunology

Abstract

Background: Peanut allergy is common, life‐threatening, and without therapeutic options. We evaluated peanut epicutaneous immunotherapy (EPIT) by using Viaskin Peanut for peanut allergy treatment. Objective: We sought to evaluate the clinical, safety, and immunologic effects of EPIT for the treatment of peanut allergy. Methods: In this multicenter, double‐blind, randomized, placebo‐controlled study, 74 participants with peanut allergy (ages 4‐25 years) were treated with placebo (n = 25), Viaskin Peanut 100 &mgr;g (VP100; n = 24) or Viaskin Peanut 250 &mgr;g (VP250; n = 25; DBV Technologies, Montrouge, France). The primary outcome was treatment success after 52 weeks, which was defined as passing a 5044‐mg protein oral food challenge or achieving a 10‐fold or greater increase in successfully consumed dose from baseline to week 52. Adverse reactions and mechanistic changes were assessed. Results: At week 52, treatment success was achieved in 3 (12%) placebo‐treated participants, 11 (46%) VP100 participants, and 12 (48%) VP250 participants (P = .005 and P = .003, respectively, compared with placebo; VP100 vs VP250, P = .48). Median change in successfully consumed doses were 0, 43, and 130 mg of protein in the placebo, VP100, and VP250 groups, respectively (placebo vs VP100, P = .014; placebo vs VP250, P = .003). Treatment success was higher among younger children (P = .03; age, 4‐11 vs >11 years). Overall, 14.4% of placebo doses and 79.8% of VP100 and VP250 doses resulted in reactions, predominantly local patch‐site and mild reactions (P = .003). Increases in peanut‐specific IgG4 levels and IgG4/IgE ratios were observed in peanut EPIT‐treated participants, along with trends toward reduced basophil activation and peanut‐specific TH2 cytokines. Conclusions: Peanut EPIT administration was safe and associated with a modest treatment response after 52 weeks, with the highest responses among younger children. This, when coupled with a high adherence and retention rate and significant changes in immune pathways, supports further investigation of this novel therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jaci.2016.08.017

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

See all 314

Metadata

Authors
Jones, S. M., Sicherer, S. H., Burks, A. W., Leung, D. Y. M., Lindblad, R. W., Dawson, P., Henning, A. K., Berin, M. C., Chiang, D., Vickery, B. P., Pesek, R. D., Cho, C. B., Davidson, W. F., Plaut, M., Sampson, H. A., & Wood, R. A.
Venue
Journal of Allergy and Clinical Immunology
Publisher
Elsevier BV
Published
2017-04
Volume
139
Issue
4
Pages
1242-1252.e9
ISSN
0091-6749 (ISSN-L)
OpenAlex
W2541170535
Cited by
314
References
33
FWCI
35.55
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults. https://app.cochat.ai/papers/10.1016/j.jaci.2016.08.017
The paper
Jones, S. M., Sicherer, S. H., Burks, A. W., Leung, D. Y. M., Lindblad, R. W., Dawson, P., Henning, A. K., Berin, M. C., Chiang, D., Vickery, B. P., Pesek, R. D., Cho, C. B., Davidson, W. F., Plaut, M., Sampson, H. A., & Wood, R. A. (2017). Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2016.08.017

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.